Johnson & Johnson (JNJ): Price and Financial Metrics


Johnson & Johnson (JNJ)

Today's Latest Price: $147.06 USD

0.05 (-0.03%)

Updated Sep 29 4:00pm

Add JNJ to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

JNJ Stock Summary

  • JNJ has a higher market value than 99.75% of US stocks; more precisely, its current market capitalization is $387,314,661,407.
  • Johnson & Johnson's stock had its IPO on January 1, 1986, making it an older stock than 92.87% of US equities in our set.
  • In terms of volatility of its share price, JNJ is more volatile than merely 0.44% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Johnson & Johnson are WMT, PG, TSM, MA, and TSLA.
  • Visit JNJ's SEC page to see the company's official filings. To visit the company's web site, go to www.jnj.com.
JNJ Daily Price Range
JNJ 52-Week Price Range

JNJ Stock Price Chart Technical Analysis Charts


JNJ Price/Volume Stats

Current price $147.06 52-week high $157.00
Prev. close $147.11 52-week low $109.16
Day low $146.06 Volume 6,770,256
Day high $147.92 Avg. volume 8,385,094
50-day MA $148.72 Dividend yield 2.75%
200-day MA $145.17 Market Cap 387.18B

Johnson & Johnson (JNJ) Company Bio


Johnson & Johnson researches and develops, manufactures, and sells various products in the health-care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. Some of its well-known brands include Tylenol-fever, Listerine-bad breath, Splenda-no-calorie sweetener, Neutrogena-skin care, Pepcid-heartburn, Zyrtec - allergy, Motrin-ibuprofen, Sudafed-allergy, and plenty more. The company was founded in 1885 and is based in New Brunswick, New Jersey.

JNJ Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$147.06$64.04 -56%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Johnson & Johnson. To summarize, we found that Johnson & Johnson ranked in the 26th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 56.17%. The most interesting components of our discounted cash flow analysis for Johnson & Johnson ended up being:

  • The company has produced more trailing twelve month cash flow than 97.53% of its sector Healthcare.
  • The business' balance sheet reveals debt to be 7% of the company's capital (with equity being the remaining amount). Approximately just 17.83% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • JNJ's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 41.06% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-57%
1%-57%
2%-56%
3%-56%
4%-56%
5%-55%

Want more companies with a valuation profile/forecast similar to that of Johnson & Johnson? See A, IONS, VIVO, HSIC, and RMD.


JNJ Latest News Stream


Event/Time News Detail
Loading, please wait...

JNJ Latest Social Stream


Loading social stream, please wait...

View Full JNJ Social Stream

Latest JNJ News From Around the Web

Below are the latest news stories about Johnson & Johnson that investors may wish to consider to help them evaluate JNJ as an investment opportunity.

Johnson & Johnson stock rises Monday, still underperforms market

Yahoo | September 28, 2020

Dr. Fauci just said something surprising about coronavirus vaccines and face masks

Several coronavirus vaccine trials will soon be finished and some of the frontrunners might be deemed safe and effective for emergency use. Health officials from the World Health Organization and Dr. Anthony Fauci warn that the arrival of COVID-19 vaccines won't be enough to reduce the transmission of the illness anytime soon. Fauci says that precautionary measures including face masks, social distancing, and frequent handwashing will need to continue even after vaccines arrive. The FDA will host a significant coronavirus vaccine meeting in just a few weeks, at which point we might find out more details about the progress of experimental drugs that have reached the final phase of testing. Vaccine candidates from AstraZeneca/Oxford, Pfizer/BioNTech, and Moderna have Phase 3 trials underw...

BGR | September 27, 2020

The Week Ahead In Biotech: FDA Decisions For Mesoblast And Eton, Coronavirus Vaccine Updates

Biotech stock reversed course last week, dragged lower by the broader market weakness. The week's news flow was headlined by Johnson & Johnson (NYSE: JNJ ) kickstarting a Phase 3 trial of its coronavirus vaccine candidate. A few clinical readouts released during the week triggered strong moves. Vaccinex Inc (NASDAQ: VCNX ) and AC Immune SA (NASDAQ: ACIU ) were among the worst decliners of the week, with the former reacting to a failed mid-stage trial of lead drug in Huntington's disease, while the latter plunged after an out-licensed Alzheimer's drug flunked a mid-stage trial. Here are the key catalysts for the unfolding week. Conferences World Muscle Society, or WMS, 25: Virtual Congress: Sept. 28-Oct. 2 Annual Northeast Amyotrophic Lateral Sclerosis, or NEALS, meeting: Sept. 30- Oct. ...

Benzinga | September 26, 2020

3 Stocks to Help You Build Retirement Wealth

Investing in stocks should be part of every retirement plan; it's one of the best ways to build wealth for your golden years. If you're approaching retirement and short of your savings goals, you need to put your money to work so you can live a comfortable retired life. Here are three top stocks that could add significantly to your retirement wealth.

Yahoo | September 26, 2020

Point/Counterpoint: The Case for Peloton

By Geoffrey Smith  and Peter Nurse

Yahoo | September 26, 2020

Read More 'JNJ' Stories Here

JNJ Price Returns

1-mo -4.28%
3-mo 5.46%
6-mo 11.95%
1-year 16.75%
3-year 22.60%
5-year 80.71%
YTD 2.84%
2019 16.22%
2018 -5.13%
2017 24.43%
2016 15.33%
2015 1.14%

JNJ Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full JNJ Dividend History

Continue Researching JNJ

Want to see what other sources are saying about Johnson & Johnson's financials and stock price? Try the links below:

Johnson & Johnson (JNJ) Stock Price | Nasdaq
Johnson & Johnson (JNJ) Stock Quote, History and News - Yahoo Finance
Johnson & Johnson (JNJ) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7417 seconds.